徹底解説！　糖尿病治療薬　選び方・使い方

出版社： 文光堂
著者：
発行日： 2021-02-05
分野： 臨床医学：内科  >  糖尿病
ISBN： 9784830613968
電子書籍版： 2021-02-05 （第1版第2刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,950 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,950 円(税込)

購入する

商品紹介

近年，新規糖尿病治療薬の発売が続き，使用する薬物の選択肢が増えた一方で，薬物の選択方法は複雑かつ難しくなった．本書では，年齢や性，糖尿病の型や病態，罹病期間，合併症や併存症の有無だけでなく，疾患や治療に対する患者の思い，経済的状況を含む家庭環境など，さまざまな患者の状況において，最適と思われる薬物の選択方法の考え方や根拠を解説している．また，さまざまな条件を持つ典型症例も提示し，処方に至る過程をより実感できるような工夫もしている．さらに，病態別に選択するべき薬物が一目でわかる早見表も付録として添えた．ガイドラインに記載されている一般的な原則と臨床医の経験則をつなぎ，最適な薬物選択に最短距離でたどり着くための一冊．

目次

  • I章　糖尿病薬物療法の基本
    　1　糖尿病の病態
    　2　糖尿病の診断と検査
    　3　糖尿病の治療戦略

    II章　各種糖尿病治療薬の基本知識
    　1　ビグアナイド薬
    　2　チアゾリジン薬
    　3　DPP-4阻害薬
    　4　スルホニル尿素（SU）薬
    　5　速効型インスリン分泌促進薬（グリニド薬）
    　6　SGLT2阻害薬
    　［COLUMN］イメグリミン塩酸塩
    　7　α-グルコシダーゼ阻害薬
    　8　経口GLP-1受容体作動薬（経口セマグルチド）
    　9　配合薬
    　10　GLP-1受容体作動薬
    　11　インスリン
    　12　配合注射薬
    　［COLUMN］GIP/GLP-1受容体デュアルアゴニスト

    III章　病態・状況別の薬物療法
    　1　肥満，インスリン抵抗性を伴う糖尿病
    　2　やせ，インスリン分泌不全を伴う2型糖尿病
    　3　妊娠糖尿病，糖尿病合併妊娠
    　4　小児糖尿病
    　5　高齢糖尿病
    　6　腎機能障害合併糖尿病
    　7　虚血性心疾患合併糖尿病
    　8　肝機能障害（NAFLD）合併糖尿病
    　9　ステロイド治療中の糖尿病
    　10　1型糖尿病への経口糖尿病治療薬の選択
    　11　2型糖尿病へのインスリン治療─経口糖尿病治療薬とインスリン注射との併用─
    　12　薬剤費を軽減したい場合
    　13　周術期・絶食検査時の薬剤中止と再開
    　14　シックデイ時の薬剤調整

    IV章　症例から考える薬物療法
    　1　健診で初めて糖尿病を指摘された症例
    　2　10年間放置された糖尿病症例
    　3　シフトワーカー　服薬コンプライアンス不良の症例
    　4　高齢者でサルコペニアと認知症を合併した症例
    　5　糖尿病性腎症を合併する症例
    　6　周術期に経口薬中断，インスリン，経口薬再開した症例
    　7　高度肥満の合併症例
    　8　心不全と虚血性心疾患の合併症例

    V章　付録
    　1　病態別薬剤選択早見表
    　2　糖尿病治療薬一覧表

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I章 糖尿病薬物療法の基本

P.15 掲載の参考文献
1) 日本糖尿病学会編・著 : 糖尿病治療ガイド 2020-2021, 文光堂, 2020
 
2) 日本糖尿病・妊娠学会編 : 妊婦の糖代謝異常 診療・管理マニュアル, 改訂第2版, メジカルビュー社, 2018
 
P.27 掲載の参考文献
1) Inzucchi, SE et al : Management of Hyperglycemia in Type 2 Diabetes : A Patient-Centered Approach : Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35 (6) : 1364-1379, 2012
 
2) 日本糖尿病学会編・著: 糖尿病治療ガイド 2020-2021, 文光堂, 2020
 
3) Davies, MJ et al : Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41 (12) : 2669-2701, 2018
 
4) American Diabetes Association : 8. Obesity Management for the Treatment of Type 2 Diabetes : Standards of Medical Care in Diabetes-2020. Diabetes Care 43 (Suppl 1) : S89-S97, 2020
PubMed

II章 各種糖尿病治療薬の基本知識

P.36 掲載の参考文献
1) 日本糖尿病学会編・著 : 糖尿病治療ガイド 2020-2021, 文光堂, 2020
 
2) 日本糖尿病学会ビグアナイド薬の適正使用に関する委員会 : メトホルミンの適正使用に関するRecommendation, (旧ビグアナイド薬の適正使用に関するRecommendation), 2012 (2020年3月18日改訂)
 
3) American Diabetes Association : 8. Obesity Management for the Treatment of Type 2 Diabetes : Standards of Medical Care in Diabetes-2020. Diabetes Care 43 (Suppl 1) : S89-S97, 2020
PubMed
P.40 掲載の参考文献
1) Loke, YK et al : Long-term Use of Thiazolidinediones and Fractures in Type 2 Diabetes : A Meta-Analysis. CMAJ 180 (1) : 32-39, 2009
PubMed
2) American Diabetes Association : 8. Obesity Management for the Treatment of Type 2 Diabetes : Standards of Medical Care in Diabetes-2020. Diabetes Care 43 (Suppl 1) : S89-S97, 2020
PubMed
3) Aso, Y et al : Low-dose Pioglitazone Increases Serum High Molecular Weight Adiponectin and Improves Glycemic Control in Japanese Patients With Poorly Controlled Type 2 Diabetes. Diabetes Res Clin Pract 85 (2) : 147-152, 2009
PubMed
4) 日本消化器病学会編 : NAFLD/NASH診療ガイドライン 2014, 南江堂, 2014
 
P.46 掲載の参考文献
1) 日本糖尿病学会編・著 : 糖尿病治療ガイド 2020-2021, 文光堂, 2020
 
2) American Diabetes Association : 9. Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes-2020. Diabetes Care 43 (Suppl 1) : S98-S110, 2020
PubMed
3) Benzaquen, M et al : Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid : Retrospective multicenter case-control study from France and Switzerland. J Am Acad Dermatol 78 (6) : 1090-1096, 2018
PubMed
4) Men, P et al : Dipeptidyl peptidase-4 inhibitors and risk of arthralgia : A systematic review and meta-analysis. Diabetes Metab 43 (6) : 493-500, 2017
PubMed
5) Aso, Y et al : Serum Level of Soluble CD26/dipeptidyl peptidase-4 (DPP-4) Predicts the Response to Sitagliptin, a DPP-4 Inhibitor, in Patients With Type 2 Diabetes Controlled Inadequately by Metformin and/or Sulfonylurea. Transl Res 159 (1) : 25-31, 2012
PubMed
P.50 掲載の参考文献
1) 日本糖尿病学会編・著 : 糖尿病専門医研修ガイドブック, 改訂第7版, 診断と治療社, 2017
 
2) Wexler, DJ : Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus. In : UpToDate, Post TW Ed), UpToDate, Waltham, MA (Accessed on July 16, 2020)
 
3) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (9131) : 837-853, 1998
 
4) Rosenstock, J et al : Effect of Linagliptin vs Glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes : the CAROLINA randomized clinical trial. JAMA 322 (12) : 1155-1166, 2019
PubMed
5) Schopman, JE et al : The incidence of mild and severe hypoglycemia in patients with type 2 diabetes mellitus treated with sulfonylureas : a systematic review and meta-analysis. Diabetes Metab Res Rev 30 (1) : 11-22, 2014
PubMed
P.54 掲載の参考文献
1) 日本糖尿病学会編・著 : 糖尿病治療ガイド 2020-2021, 文光堂, p.66, 2020
 
2) Nagashima, K et al : Sulfonylurea and non-sulfonylurea hypoglycemic agents : pharmachological properties and tissue selectivity. Diabetes Res Clin Pract 66 (Suppl 1) : S75-S78, 2004
 
3) 二井谷隆文ほか : グリニド薬/α-グルコシダーゼ阻害薬 (α-GI) 配合錠 (ミチグリニド/ボグリボース) とグリニド薬 (レパグリニド) による日内血糖変動の比較検討. Diabetes Frontier Online 5, e1-005, 2018 (http://dfo.m-review.co.jp/articles/005-e1-005/)
 
P.61 掲載の参考文献
1) Zinman, B et al : Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373 (22) : 2117-2128, 2015
PubMed
2) Neal, B et al : Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 377 (7) : 644-657, 2017
PubMed
3) Wiviott, SD et al : Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 380 (4) : 347-357, 2019
PubMed
4) Perkovic, V et al : CREDENCE Trial Investigators : Canagliflozin and Renal Outcomes in Type 2 Diabetes and nephropathy. N Engl J Med 380 (24) : 2295-2306, 2019
 
5) Shimizu, M et al : Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab 21 (2) : 285-292, 2019
PubMed
P.65 掲載の参考文献
1) 日本糖尿病学会編・著 : 糖尿病治療ガイド 2020-2021, 文光堂, 2020
 
2) Chiasson, JL et al : Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patient With Impared Glucose Tolerance : The STOP-NIDDM Trial. JAMA 290 (4) : 486-494, 2003
 
3) 山下哲郎ほか : 症例報告α-グルコシダーゼ阻害剤による腸管気腫症の1例. 京府医大誌 123 (4) : 255-262, 2014
 
P.69 掲載の参考文献
1) Marso, SP et al : Semaglutide and Cardiovascular Outcomes in patients with type 2 diabetes. N Engl J Med 375 (19) : 1834-1844, 2016
 
2) Husain, M et al : Oral Semaglutide and Cardiovascular Outcomes in patients with Type 2 Diabetes. N Engl J Med 381 (9) : 841-851, 2019
PubMed
P.72 掲載の参考文献
1) Duckworth, W et al : Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets. J Manag Care Pharm 9 (3) : 256-262, 2003
PubMed
2) Bangalore, S et al : Fixed-dose combinations improve medication compliance : A meta-analysis. Am J Med 120 (8) : 713-719, 2007
PubMed
3) Matthews, DR et al : Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY) : a 5-year, multicentre, randomised, double-blind trial. Lancet 394 (10208) : 1519-1529, 2019
PubMed
P.79 掲載の参考文献
1) American Diabetes Association : 9. Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes-2020. Diabetes Care 43 (Suppl 1) : S98-S110, 2020
PubMed
2) 日本糖尿学会編・著 : 付録 血糖降下薬一覧表・注射薬. 糖尿病治療ガイド 2020-2021, 文光堂, p.139, 2020
 
3) Nauck, MA et al : MANAGEMENT OF ENDOCRINE DISEASE : Are all GLP-1 Agonists Equal in the Treatment of Type 2 Diabetes? Eur J Endocrinol 181 (6) : R211-R234, 2019
 
4) 日本糖尿学会編・著 : Q5-9 GLP-1 受容体作動薬の特徴は何か? 糖尿病診療ガイドライン 2019, 南江堂, p.77-78, 2019
 
5) Cosentino, F et al : 2019 ESC Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases Developed in Collaboration With the EASD. Eur Heart J 41 (2) : 255-323, 2020
PubMed
P.85 掲載の参考文献
1) ノボノルディスクファーマ株式会社 : フィアスプ(R) 注 インタビューフォーム, 2019
 
2) 日本イーライリリー株式会社 : ルムジェブ(R) 注 インタビューフォーム, 2020
 
3) 日本糖尿病学会編・著 : 糖尿病治療ガイドライン 2020-2021, 文光堂, 2020
 
4) Nagase, T et al : Insulin-derived Amyloidosis and Poor Glycemic Control : A Case Series. Am J Med 127 (5) : 450-454, 2014
PubMed
5) 日本イーライリリー株式会社 : バクスミー(R) インタビューフォーム, 2020
 
P.88 掲載の参考文献
1) Kaku, K et al : Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naive Japanese patients with type 2 d iabetes in a phase 3, open-label, randomized trial. Diabetes Obes Metab 21 (12) : 2674-2683, 2019
 
P.92 掲載の参考文献
1) Bastin, M et al : Dual GIP-GLP1-receptor agonists in the treatment of type 2 diabetes : a short review on emerging data and therapeutic potential. Diabetes Metabo Syndr Obes 12 : 1973-1985, 2019
 
2) Finan, B et al : Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and human. Sci Transl Med 5 (209) : 209ra151, 2013
PubMed
3) Frias, JP et al : The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metab 26 (2) : 343-352. e2, 2017
 
4) Coskun, T et al : LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus : from discovery to clinical proof of concept. Mol Metab 18 : 3-14, 2018
PubMed
5) Frias, JP et al : Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes : a randomized, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 392 (10160) : 2180-2193, 2018
PubMed

III章 病態・状況別の薬物療法

P.98 掲載の参考文献
1) 日本肥満学会編 : 肥満症診療ガイドライン 2016, ライフサイエンス出版, 2016
 
2) 日本糖尿病学会編・著 : 糖尿病治療ガイド 2020-2021, 文光堂, 2020
 
3) American Diabetes Association : 8. Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes-2018. Diabetes Care 41 (Suppl 1) : S73-S85, 2018
 
P.104 掲載の参考文献
1) American Diabetes Association : 8. Obesity Management for the Treatment of Type 2 Diabetes : Standards of Medical Care in Diabetes-2020. Diabetes Care 43 (Suppl 1) : S89-S97, 2020
PubMed
2) 日本糖尿病学会編・著 : 糖尿病専門医研修ガイドブック, 改訂第7版, 診断と治療社, p.58-59, 2017
 
3) McDonald, TJ et al : Stability and Reproducibility of a Single-Sample Urinary C-peptide/creatinine Ratio and It Correlation With 24-h Urinary C-peptide. Clin Chem 55 (11) : 2035-2039, 2009
PubMed
4) Chen, LK et al : Sarcopenia in Asia : Consensus Report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc 15 (2) : 95-101, 2014
 
P.111 掲載の参考文献
1) Metzger, BE et al : International Association of Diabetes and Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycemia in Pregnancy. Diabetes Care 33 (3) : 676-682, 2010
PubMed
2) 日本糖尿病学会編・著 : 糖尿病専門医研修ガイドブック, 改訂第7版, 診断と治療社, 2017
 
3) American Diabetes Association : 14. Management of Diabetes in Pregnancy : Standards of Medical Care in Diabetes-2020. Diabetes Care 43 (Suppl 1) : S183-S192, 2020
 
4) 日本糖尿病・妊娠学会編 : 妊婦の糖代謝異常 診療・管理マニュアル, 改訂第2版, メジカルビュー社, 2018
 
P.116 掲載の参考文献
1) TODAY Study Group : Retinopathy in youth with type 2 diabetes participating in the TODAY clinical trial. Diabetes Care 36 (6) : 1772-1774, 2013
 
2) Zeitler, P et al : ISPAD Clinical Practice Consensus Guidelines 2018 : Type 2 diabetes mellitus in youth. Pediatr Diabetes 19 (Suppl 27) : 28-46, 2018
 
3) Laffel, L et al : Metformin monotherapy in youth with recent onset type 2 diabetes: experience from the prerandomization run-in phase of the TODAY study. Pediatr Diabetes 13 (5) : 369-375, 2012
PubMed
4) Gottschalk, M et al : Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes : a randomized, single-blind comparative study. Diabetes Care 30 (4) : 790-794, 2007
PubMed
5) Urakami, T : New insights into the pharmacological treatment of pediatric patients with type 2 diabetes. Clin Pediatr Endocrinol 27 (1) : 1-8, 2018
PubMed
P.123 掲載の参考文献
1) 日本糖尿病学会・日本老年医学会編・著 : 高齢者糖尿病治療ガイド 2018, 文光堂, p.11, 2018
 
2) Yaffe, K et al : Association between Hyperglycemia and Dementia in a Biracial Cohort of Older Adults with Diabetes Mellitus. JAMA Intern Med 173 (14) : 1300-1306, 2013
 
3) 日本糖尿病学会編・著 : 糖尿病治療ガイド 2020-2021, 文光堂, p.104, 2020
 
P.128 掲載の参考文献
1) 日本糖尿病学会編・著 : 糖尿病治療ガイド 2020-2021, 文光堂, 2020
 
2) 日本腎臓学会編・著 : エビデンスに基づくCKD診療ガイドライン 2018, 東京医学社, p.104, 2018
 
3) Yokoyama, H et al : Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes : the Japan Diabetes Clinical Data Management Study (JDDM15). Nephrol Dial Transplant 24 (4) : 1212-1219, 2009
PubMed
4) Perkovic, V et al : Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 380 (24) : 2295-2306, 2019
PubMed
P.134 掲載の参考文献
1) Tominaga, M et al : Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22 (6) : 920-924, 1999
 
2) Hanefeld, M et al : Risk factors for myocardial infarction and death in newly detected NIDDM : the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39 (12) : 1577-1583, 1996
PubMed
3) Sone, H et al : Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes : subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab 96 (11) : 3448-3456, 2011
PubMed
4) American Diabetes Association : 10. Cardiovascular Disease and Risk Management : Standards of Medical Care in Diabetes-2020. Diabetes Care 43 (Suppl 1) : S111-S134, 2020
PubMed
5) Marso, SP et al : Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375 (4) : 311-322, 2016
PubMed
P.138 掲載の参考文献
1) Browning, JD et al : Prevalence of hepatic steatosis in an urban population in the United States : Impact of ethnicity. Hepatology 40 (6) : 1387-1395, 2004
 
2) Ekstedt, M et al : Fibrosis Stage Is the Strongest Predictor for Disease-Specific Mortality in NAFLD After Up to 33 Years of Follow-Up. Hepatology 61 (5) : 1547-1554, 2015
PubMed
3) Musso, G et al : Meta-analysis : natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43 (8) : 617-649, 2011
PubMed
4) Shimizu, M et al : Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab 21 (2) : 285-292, 2019
PubMed
5) Armstrong, MJ et al : Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN) : a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387 (10019) : 679-690, 2016
 
P.144 掲載の参考文献
1) Tamez-Perez, HE et al : Steroid hyperglycemia : Prevalence, early detection and therapeutic recommendations. A narrative review. World J Diabetes 6 (8) : 1073-1081, 2015
PubMed
2) Hwang, JL et al : Steroid-induced diabetes : a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev 30 (2) : 96-102, 2014
PubMed
3) Barnes, PJ et al : Inhaled glucocorticoids for asthma. N Engl J Med 332 (13) : 868-875, 1995
PubMed
4) Faul, JL et al : High dose inhaled corticosteroids and dose dependent loss of diabetic control. BMJ 317 (7171) : 1491, 1998
PubMed
5) Clore, JN et al : Glucocorticoid-induced hyperglycemia. Endocr Prct 15 (5) : 469-474, 2009
 
P.149 掲載の参考文献
1) 日本糖尿病学会編・著 : 糖尿病診療ガイドライン 2019, 南江堂, 2019
 
2) 日本糖尿病学会編・著 : 糖尿病治療ガイド 2020-2021, 文光堂, 2020
 
3) Yamada, E et al : Effect of carbohydrate counting using bolus calculators on glycemic control in type 1 diabetes patients during continuous subcutaneous insulin infusion. J Diabetes Investig 8 (4) : 496-500, 2017
PubMed
4) 松原旭ほか : 糖尿病患者に対するα-グルコシダーゼ阻害薬ミグリトール (セイブル錠 (R)) とインスリン製剤との長期併用における安全性および有効性の検討-特定使用成績調査-. 薬理と治療 46 (5) : 739-756, 2018
 
5) The committee on the Proper Use of SGLT2 Inhibitors : Recommendations on the proper use of SGLT2 inhibitors. Diabetol Int 11 (1) : 1-5, 2019
 
P.154 掲載の参考文献
1) 日本糖尿病学会編・著 : 糖尿病治療ガイド 2020-2021, 文光堂, p.35, 2020
 
2) American Diabetes Association : 9. Pharmacologic Approaches to Glycemic Treatment : Standards of Medical care in Diabetes-2020. Diabetes Care 43 (Suppl 1) : S98-S110, 2020
PubMed
P.159 掲載の参考文献
1) Alfian, SD et al : Medication adherence contributes to an improved quality of life in type 2 diabetes mellitus patients : a cross-sectional study. Diabetes Ther 7 (4) : 755-764, 2016
 
2) American Diabetes Association : 9. Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes-2020. Diabetes Care 43 (Suppl 1) : S98-S110, 2020
PubMed
3) Weinstein, M et al : Critical ratios and efficient allocation. J Pub Econ 2 (2) : 147-157, 1973
 
4) Charokopou, M et al : The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of type 2 diabetes mellitus. Diabet Med 32 (7) : 890-898, 2015
 
5) Shah, D et al : Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk : a US-managed care perspective. Clinicoecon Outcomes Res 10 : 791-803, 2018
PubMed
P.166 掲載の参考文献
1) Khan, NA et al : Perioperative management of blood glucose in adults with diabetes mellitus. In : UpToDate, Post TW (Ed), Waltham, MA (Accessed on July 16, 2020)
 
2) 日本糖尿病学会編・著 : 糖尿病専門医研修ガイドブック, 改訂第7版, 診断と治療社, 2017
 
3) American Diabetes Association : 15. Diabetes Care in the Hospital : Standards of Medical Care in Diabetes-2020. Diabetes Care 43 (Suppl 1) : S193-S202, 2020
 
4) Umpierrez, GE et al : Randomized Study of Basal-Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes Undergoing General Surgery (RABBIT 2 Surgery). Diabetes Care 34 (2) : 256-261, 2011
PubMed
5) 日本糖尿病学会ビグアナイド薬の適正使用に関する委員会 : メトホルミンの適正使用に関するRecommendation (旧ビグアナイド薬の適正使用に関するRecommendation), 2012 (2020年3月18日改訂)
 
P.171 掲載の参考文献
1) 日本糖尿病学会編・著 : 糖尿病診療ガイドライン 2019, 南江堂, 2019
 
2) 日本糖尿病学会ビグアナイド薬の適正使用に関する委員会 : メトホルミンの適正使用に関するRecommendation (旧 : ビグアナイド薬の適正使用に関するRecommendation), 2012 (2020年3月18日改訂)
 
3) 日本糖尿病学会SGLT2阻害薬の適正使用に関する委員会 : SGLT2阻害薬の適正使用に関するRecommendation, 2014 (2019年8月6日改訂)
 

IV章 症例から考える薬物療法

P.176 掲載の参考文献
1) 日本糖尿病学会編・著 : 糖尿病治療ガイド 2020-2021, 文光堂, p.37, 2020
 
2) American Diabetes Association : 9. Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes-2020. Diabetes Care 43 (Suppl 1) : S98-S110, 2020
PubMed
P.179 掲載の参考文献
1) Rosenstock, J et al : Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk. JAMA 321 (1) : 69-79, 2019
PubMed
2) American Diabetes Association : 9. Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes-2020. Diabetes Care 43 (Suppl 1) : S98-S110, 2020
PubMed
3) Mann, JFE et al : Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med 377 (9) : 839-848, 2017
PubMed
P.182 掲載の参考文献
1) Antunes, LC et al : Obesity and shift work : chronobiological aspects. Nutr Res Rev 23 (1) : 155-168, 2010
PubMed
2) Gan, Y et al : Shift work and diabetes mellitus : a meta-analysis of observational studies. Occup Environ Med 72 (1) : 72-78, 2015
PubMed
P.185 掲載の参考文献
1) Kadowaki, T et al : Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus : a randomized, double-blind, placebo-controlled study with an open-label, long-term extension. Diabetes Obes Metab 16 (5) : 418-425, 2014
PubMed
2) 日本糖尿病学会SGLT2阻害薬に関する委員会 : SGLT2阻害薬の適正使用に関するRecommendation, 2014 (2019年8月6日改訂)
 
P.187 掲載の参考文献
1) Perkovic, V et al : Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 380 (24) : 2295-2306, 2019
PubMed
2) American Diabetes Association : 9. Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes-2020. Diabetes Care 43 (Suppl 1) : S98-S110, 2020
PubMed
P.192 掲載の参考文献
1) 日本糖尿病学会編・著 : 糖尿病専門医研修ガイドブック, 改訂第7版, 診断と治療社, 2017
 
2) 日本糖尿病学会編・著 : 糖尿病治療ガイド 2020-2021, 文光堂, 2020
 
3) van den Berghe, G et al : Intensive Insulin Therapy in Critically Ill Patients. N Engl J Med 345 (19) : 1359-1367, 2001
 
4) The NICE-SUGAR Study Investigators : Intensive versus Conventional Glucose Control in Critically Ill Patients. N Engl J Med 360 (13) : 1283-1297, 2009
 
P.196 掲載の参考文献
1) Zinman, B et al : Empagliflozin, cardiovascular outcomes, and mortality in type 2 Diabetes. N Engl J Med 373 (22) : 2117-2128, 2015
PubMed
2) Wanner, C et al : Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (4) : 323-334, 2016
PubMed
3) Marso, SP et al : Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (4) : 311-322, 2016
PubMed
4) Ribaric, G et al : Diabetes and weight in comparative studies of bariatric surgery vs conventional medical therapy : a systematic review and meta-analysis. Obes Surg 24 (3) : 437-455, 2014
PubMed
5) Chang, SH et al : The effectiveness and risks of bariatric surgery : an updated systematic review and meta-analysis, 2003-2012. JAMA Surg 149 (3) : 275-287, 2014
PubMed
6) Yan, Y et al : Roux-en-Y gastric bypass versus medical treatment for type 2 diabetes mellitus in obese patients : A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 95 (17) : e3462, 2016
 
7) Sjostrom, L : Review of the key results from the Swedish Obese Subjects (SOS) trial-a prospective controlled intervention study of bariatric surgery. J Intern Med 273 (3) : 219-234, 2013
 
P.199 掲載の参考文献
1) American Diabetes Association : Standards of Medical Care in Diabetes-2020. Diabetes Care 43 (Suppl 1) : S1-S121, 2020
 
2) Nakatani, Y et al : Effects of GLP-1 Receptor Agonists on Heart Rate and the Autonomic Nervous System Using Holter Electrocardiography and Power Spectrum Analysis of Heart Rate Variability. Diabetes Care 39 (2) : e22-e23, 2016
 
3) Margulies, KB et al : Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction : A Randomized Clinical Trial. JAMA 316 (5) : 500-508, 2016
PubMed
4) Mazzone, T et al : Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes : a randomized trial. JAMA 296 (21) : 2572-2581, 2006
PubMed
5) Gaede, P et al : Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358 (6) : 580-591, 2008
PubMed

書評

最近チェックした商品履歴

Loading...